5 Stock in Different Moves: Cyberark Software Ltd (NASDAQ:CYBR), CenturyLink (NYSE:CTL), Ladenburg Thalmann Financial Services (NYSEMKT:LTS), Ultragenyx Pharmaceutical (NASDAQ:RARE), Netlist Inc. (NASDAQ:NLST)


Cyberark Software Ltd (NASDAQ:CYBR) announced Total revenue was $36.3 million, up 81% year-over-year compared with the fourth quarter of 2013. License revenue was $24.4 million, up 95% compared with the fourth quarter of 2013. Maintenance and Professional Services revenue was $11.9 million, up 57% year-over-year. On Thursday shares of Cyberark Software Ltd (NASDAQ:CYBR) closed at $45.69. Company’s EPS growth for next 5 years is recorded as 5.80%.

CenturyLink Inc. (NYSE:CTL) posted fourth-quarter 2014 adjusted earnings of 60 cents per share, below the Zacks Consensus Estimate of 63 cents. GAAP net income stood at $188 million or 33 cents per share compared with a net income of $239 million or 41 cents per share in the prior-year quarter. CenturyLink, Inc. (NYSE:CTL) in last trading activity moved down -3.04% to close at $39.29. Company weekly performance is 2.24% while its quarterly performance stands at -0.41%. CenturyLink, Inc. (NYSE:CTL) is -11.67% away from its 52 week high.

Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) confirmed the first quarter 2015 monthly cash dividends for its 8.00% Series A Cumulative Redeemable Preferred Stock. The $0.1667 per share dividend is payable on 2 march on the record date of 15 February. On last trading day Ladenburg Thalmann Financial Services Inc. (NYSEMKT:LTS) advanced 0.25% to close at $3.94. Its volatility for the week is 3.04% while volatility for the month is 2.99%. LTS’s sales growth for past 5 years was 45.60% and its EPS growth for past 5 years was 19.70%. Ladenburg Thalmann Financial Services Inc. (NYSEMKT:LTS) monthly performance is 0.25%.

On 10 February, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), announced the presentation of positive 36-week data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has 0.70% insider ownership while its institutional ownership stands at 92.40%. In last trading activity company’s stock closed at $53.98.

Netlist, Inc. (NASDAQ: NLST) announced that the U.S. Court of Appeals for the Federal Circuit denied an emergency motion from Diablo Technologies, Inc., asking the Federal Circuit to stay the preliminary injunction entered against controller chips used by Sandisk Corp. (NASDAQ: SNDK) in its high-speed ULLtraDIMM SSD product line. On last trading day Netlist Inc. (NASDAQ:NLST) advanced 2.76% to close at $1.86. Its volatility for the week is 11.04% while volatility for the month is 11.04%. NLST’s sales growth for past 5 years was -19.30% and its EPS growth for past 5 years was 14.60%. Netlist Inc. (NASDAQ:NLST) monthly performance is 39.85%.


Leave a Reply

Your email address will not be published. Required fields are marked *